Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma

BACKGROUND AND OBJECTIVE: The recurrence occurs within 5 years in up to 70% of hepatocellular carcinoma (HCC) patients who received radical liver resection, and most patients are no longer suitable for repeat surgery. There are limited treatment options for unresectable recurrent HCC. This study aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ze, Jiao, Tianyu, Li, Junfeng, Hu, Bingyang, Zhang, Wenwen, Wang, Zhijun, Wan, Tao, Wang, Yafei, Lu, Shichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938599/
https://www.ncbi.nlm.nih.gov/pubmed/36803872
http://dx.doi.org/10.1186/s12957-023-02939-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938599/
https://www.ncbi.nlm.nih.gov/pubmed/36803872
http://dx.doi.org/10.1186/s12957-023-02939-5

Ejemplares similares